Table 1.
Baseline comparisons, length of stay, and length of follow-up for 972 dogs in an intranasal vaccine trial at a shelter in the USAa
| Variable | Vaccine group |
Test statistic | P | |||||||||||||
| IN-BP (n=308) |
IN-BPA (n=353) |
IN-P (n=311) |
||||||||||||||
| n | % | n | % | n | % | |||||||||||
| Gender | ||||||||||||||||
| Male | 159 | 51.6 | 185 | 52.4 | 154 | 49.5 | χ2=0.58 | 0.75 | ||||||||
| Female | 149 | 48.4 | 168 | 47.6 | 157 | 50.5 | ||||||||||
| Spay/neuter status | ||||||||||||||||
| Intact or unknown | 268 | 87.0 | 294 | 83.3 | 274 | 88.1 | χ2=3.57 | 0.17 | ||||||||
| Spayed or castrated | 40 | 13.0 | 59 | 16.7 | 37 | 11.9 | ||||||||||
| Breed | ||||||||||||||||
| Purebreed or only one breed given | 88 | 28.6 | 100 | 28.3 | 73 | 23.5 | χ2=2.66 | 0.26 | ||||||||
| Mixed breed | 220 | 71.4 | 253 | 71.7 | 238 | 76.5 | ||||||||||
| Admission status | ||||||||||||||||
| Owned (surrendered/abandoned) | 177 | 57.5 | 192 | 54.4 | 158 | 50.8 | χ2=2.77 | 0.25 | ||||||||
| Stray | 131 | 42.5 | 161 | 45.6 | 153 | 49.2 | ||||||||||
| Prior vaccine history | ||||||||||||||||
| Current or overdue | 12 | 3.9 | 19 | 5.4 | 8 | 2.6 | χ2=3.41 | 0.18 | ||||||||
| Never or unknown | 296 | 96.1 | 334 | 94.6 | 303 | 97.4 | ||||||||||
|
Median (minimum–maximum) |
|
|
|
|
|
|||||||||||
| IN-BP |
IN-BPA |
IN-P |
||||||||||||||
| Age (months) | 7.0 (2–120) | 9.0 (2–146) | 8.0 (2–156) | KW=2.66 | 0.26 | |||||||||||
| Days of stay at TCHS | 7.0 (1–30) | 7.0 (1–30) | 8.0 (1–30) | KW=3.21 | 0.20 | |||||||||||
| Days of follow-up | 10.0 (1–30) | 11.0 (1–30) | 10.0 (1–30) | KW=1.90 | 0.39 | |||||||||||
a
IN-P: intranasal placebo; IN-BP: intranasal vaccine with B. bronchiseptica and canine-parainfluenza virus; IN-BPA: intranasal vaccine with B. bronchiseptica, canine-parainfluenza virus, and canine-adenovirus. Test statistics: χ2; KW: Kruskal–Wallis.